Abstract
Antimicrobial resistance (AMR) poses a serious threat to global health, potentially causing 10 million deaths per year globally by 2050. To tackle AMR, researchers from all around the world have generated a selection of various formulated (viz. nanoparticulate, liposomal) therapeutic combinations to be evaluated for new antimicrobial drug discovery. To meet the urgent need for accelerating new antibacterial drug development, we need rapid but reliable whole-cell assay methods and models to test formulated therapeutic combinations against several pathogens in different in vitro conditions as models of actual infections.
Over the past two decades, high-throughput spot-culture growth inhibition assay (HT-SPOTi) has been demonstrated to be a gold-standard drug susceptibility method for evaluating novel chemotherapeutic entities and existing drugs against various microbes of global concern. Our modified HT-SPOTi method serves the purpose of evaluating drug combinations against Gram-positive/negative microorganisms as well as acid-fast bacilli. The newly developed and modified HT-SPOTi assay builds upon the limitations of our previously published method to incorporate antimicrobial susceptibility testing with formulated therapeutic combinations. The modified HT-SPOTi is compared with a range of other antimicrobial susceptibility testing methods and validated using a library of existing antibiotics as well as formulated therapeutic combinations. The modified HT-SPOTi assay can serve as an efficient and reliable high-throughput drug screening platform to discover new potential antimicrobial molecules, including as part of therapeutic formulations.
This chapter describes the generation of drug susceptibility profile for formulated therapeutic combinations using modified HT-SPOTi in a semi-automated system.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Murray CJ, Ikuta KS, Sharara F et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629–655
Saifullah B, Chrzastek A, Maitra A et al (2017) Novel anti-tuberculosis nano delivery formulation of ethambutol with graphene oxide. Molecules 22(10):1560
Wang Y, Grainger DW (2022) Regulatory considerations specific to liposome drug development as complex drug products. Front Drug Deliv 2:901281
Evangelopoulos D, Bhakta S (2010) Rapid methods for testing inhibitors of mycobacterial growth. Methods Mol Biol 642:193–201
Daraee H, Etemadi A, Kouhi M et al (2016) Application of liposomes in medicine and drug delivery. Artif Cells Nanomedicine Biotechnol 44:381–391
Danquah CA, Maitra A, Gibbons S, et al (2016) HT-SPOTi: a rapid drug susceptibility test (DST) to evaluate antibiotic resistance profiles and novel chemicals for anti-infective drug discovery. 17.8.1–17.8.12
Collins LA, Franzblau SG (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004–1009
WHO Global antimicrobial resistance and use surveillance system (GLASS) report, https://www.who.int/publications/i/item/9789240062702
Mayorga-Ramos A, Zúñiga-Miranda J, Carrera-Pacheco SE et al (2023) CRISPR-Cas-based antimicrobials: design, challenges, and bacterial mechanisms of resistance. ACS Infect Dis 9(7):1283–1302
Slater KB, Kim D, Chand P et al (2023) A current perspective on the potential of nanomedicine for anti-tuberculosis therapy. Trop Med Infect Dis 8:100
Daniel C, Bhakta S (2022) Immunobiology of tubercle bacilli and prospects of immunomodulatory drugs to tackle tuberculosis (TB) and other non-tubercular mycobacterial infections. Immunobiology 227:152224
Ho Yi Chan S, Sheikh K, Zariwala MG et al (2023) Dry powder formulation of azithromycin for COVID-19 therapeutics. J Microencapsul 40:1–37
Bulbake U, Doppalapudi S, Kommineni N et al (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9:12
Nsairat H, Khater D, Sayed U et al (2022) Liposomes: structure, composition, types, and clinical applications. Heliyon 8:e09394
Liu P, Chen G, Zhang J (2022) A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules 27:1372
Sercombe L, Veerati T, Moheimani F et al (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286
Amin M, Huang W, Seynhaeve ALB et al (2020) Hyperthermia and temperature-sensitive nanomaterials for spatiotemporal drug delivery to solid tumors. Pharmaceutics 12:1–23
Rizi K, Murdan S, Danquah CA et al (2015) Development of a rapid, reliable and quantitative method – “SPOTi” for testing antifungal efficacy. Microbiol Methods 117:36–40
Mursaleen L, Chan SHY, Noble B et al (2023) Curcumin and n-acetylcysteine nanocarriers alone or combined with deferoxamine target the mitochondria and protect against neurotoxicity and oxidative stress in a co-culture model of Parkinson’s disease. Antioxidants (Basel) 12:130
Lee MK (2020) Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics 12:264
Guzman JD, Gupta A, Evangelopoulos D et al (2010) Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. J Antimicrob Chemother 65:2101–2107
Šturm L, Ulrih NP (2021) Basic methods for preparation of liposomes and studying their interactions with different compounds, with the emphasis on polyphenols. Int J Mol Sci 22:6547
Mialon M, Tang Y, Singh AK et al (2012) Effects of preparation and storage of agar media on the sensitivity of bacterial forward scattering patterns. Open J Appl Sci 01:26–35
Acknowledgments
Formulated therapeutic combinations were kindly gifted to us by Dr. Satyanarayana Somavarapu from the UCL School of Pharmacy. We thank Dr. Veronique Seidel from the University of Strathclyde for critically reviewing the chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Navaratnarajah, A., Daniel, C., Bhakta, S. (2024). Modified HT-SPOTi: An Antimicrobial Susceptibility Testing to Evaluate Formulated Therapeutic Combinations Against Bacterial Growth and Viability. In: Gillespie, S.H. (eds) Antibiotic Resistance Protocols. Methods in Molecular Biology, vol 2833. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3981-8_4
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3981-8_4
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3980-1
Online ISBN: 978-1-0716-3981-8
eBook Packages: Springer Protocols